Key result
Anticoagulation therapy and thromboprophylaxis management in elderly patients with hip fractures and coagulopathies lacks a universal consensus.
This review highlights the ongoing debate and lack of universal consensus regarding thromboprophylaxis management in elderly patients with hip fractures and coagulopathies.
Lack of consensus on anticoagulation in elderly hip fracture patients with coagulopathies warrants individualized decisions; leaves open need for prospective trials to guide practice.
Hip fractures in the elderly population have become a ‘disease’ with increasing incidence. Most of the geriatric patients are affected by a number of comorbidities. Coagulopathies continue to be a special point of interest for the orthopaedic trauma surgeon, with the management of this high-risk group of patients a hot topic of debate among the orthopaedic community. While a universal consensus on how to manage thromboprophylaxis for this special cohort of patients has not been reached, multiple attempts to define a widely accepted protocol have been published. Cite this article: Ktistakis I, Giannoudis V, Giannoudis PV. Anticoagulation therapy and proximal femoral fracture treatment: an update. EFORT Open Rev 2016;1:310-315. DOI: 10.1302/2058-5241.1.160034.
No takes yet. Share an insight, caveat, or question.
Ktistakis et al. (2016) conducted a review in Hip fractures and coagulopathies. Anticoagulation therapy was evaluated. Anticoagulation therapy and thromboprophylaxis management in elderly patients with hip fractures and coagulopathies lacks a universal consensus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: